Biological
Heparin sodium - Hipolabor
Heparin sodium - Hipolabor is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed133%
unknown267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients
NCT00894673
unknownphase_2
Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
NCT00934167
unknownphase_3
Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.
NCT00914472
Clinical Trials (3)
Showing 3 of 3 trials
NCT00894673Phase 3
Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients
NCT00934167Phase 2
Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
NCT00914472Phase 3
Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3